You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

PET Imaging in Colorectal Cancer

Version: 2 ID: PET 1 Version 2 nov 2010
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
K. Chan, S. Welch, C. Walker-Dilks, A.O. Raifu, Ontario PET Steering Committee

Patient Population

Patients with colorectal cancer.

Intended Guideline Users

To guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imaging and in guiding priorities for future PET imaging research.

Research Question(s)

  1. What benefit to clinical management does positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) contribute to the diagnosis or staging of colorectal cancer?
  2. What benefit to clinical management does PET or PET/CT contribute to the assessment of treatment response for colorectal cancer?
  3. What benefit to clinical management does PET or PET/CT contribute when the recurrence of colorectal cancer is suspected but not proven?
  4. What benefit to clinical management does PET or PET/CT contribute to restaging at the time of the documented recurrence for colorectal cancer?
  5. What is the role of PET when a solitary metastasis is identified at the time of recurrence and a metastectomy is being contemplated?
pdf download Summary (PDF) (229.39 Ko)
pdf download Full Report (PDF) (675.52 Ko)